Omnicell, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also presents unaudited fourth-quarter results. Omnicell provides medication-management automation, pharmacy software, adherence products, and related services; it reports as one operating segment.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $892.2 million | $897.0 million | Down 1% |
| Gross profit / margin | $413.3 million / 46.3% | $436.9 million / 48.7% | Down 5%; margin down 2.4 points |
| Operating income / margin | $35.5 million / 4.0% | $78.4 million / 8.7% | Down 55% |
| Net income / diluted EPS | $32.2 million / $0.74 | $61.3 million / $1.43 | Down 48% |
| Operating cash flow | $185.9 million | $145.0 million | Up $40.9 million |
| Cash and cash equivalents at year-end | $485.9 million | $127.2 million | Up $358.7 million |
| Working capital | $553.0 million | $246.2 million | Current ratio 3.0x vs. 2.0x |
Product revenue fell 4% to $636.0 million; services and other revenue rose 8% to $256.2 million. Services were 29% of revenue, up from 26%. U.S. revenue was $797.6 million, or 89% of the total. Product bookings increased 23% to $1.002 billion, and backlog rose to $924 million from $588 million; management cautions that backlog is not necessarily indicative of future sales.
Fourth-quarter revenue was $249.2 million versus $248.3 million a year earlier. Gross profit was $123.7 million versus $123.6 million; operating income was $20.2 million versus $22.2 million; net income was $16.4 million versus $22.1 million. Q4 diluted EPS was $0.37 versus $0.51.
Cash, debt, and significant transactions
Operating cash flow improved, while investing cash outflow increased to $279.9 million, primarily reflecting the $225 million 340B Link acquisition, $22.8 million of capital expenditures, and $32.0 million of external software development costs. Financing cash inflow was $456.3 million, principally reflecting the convertible-note issuance.
In September 2020, Omnicell issued $575 million of 0.25% convertible senior notes due 2025. The year-end carrying amount was $467.2 million, net of discount and issuance costs; disclosed fair value was $782.3 million. No revolving-credit borrowings were outstanding at year-end under the $500 million facility, and the company reported compliance with its covenants. The notes’ conversion, dilution, and potential cash-settlement terms merit attention.
Omnicell acquired 340B Link for $225 million in cash on October 1, 2020. From acquisition through year-end, it contributed $10.2 million of revenue and $1.3 million of earnings. The acquisition added $161.1 million of preliminary goodwill. The company also repurchased approximately $53 million of shares alongside the notes offering.
Changes, outlook, and risks
- COVID-19 delayed customer purchasing decisions and installations and reduced product revenue; management said customers began returning to pre-pandemic purchasing patterns in Q3. The pandemic’s future effects remained uncertain.
- Lower revenue, fixed product costs, restructuring expenses, and higher software amortization weighed on gross margin. Operating expenses increased 5%, including acquisition and employee-related costs, partly offset by pandemic-related cost savings.
- The company recorded a $2.8 million income-tax benefit in 2020, compared with $12.6 million of tax expense in 2019; equity-compensation tax benefits and research credits were principal favorable factors.
- Management expressed confidence in the business and said cash, expected operating cash flows, and available credit should meet needs for at least twelve months. The filing provides no specific FY2021 revenue or earnings guidance.
- Strategy centers on the autonomous pharmacy vision, including investment in cloud-based offerings, automation, analytics, and technology-enabled services. Risks include healthcare customer budget constraints, installation delays, competition, supply-chain concentration, cybersecurity and privacy obligations, and execution and integration of acquisitions.
- Legal matters include an Illinois biometric-privacy class action and a trade-secret lawsuit brought by Becton, Dickinson and Company. The company stated that potential losses were reasonably possible but not probable, had recorded no material accrual, and could not reasonably estimate a loss range.
Most important facts for investors to verify
- Whether elevated bookings and backlog convert into installations, recognized revenue, and cash collections on schedule.
- Whether gross margin and operating profitability recover after the 2020 declines and restructuring costs.
- The ongoing cash-flow, dilution, and accounting effects of the $575 million convertible notes, including the notes’ market value relative to carrying value.
- 340B Link integration, subsequent performance, and the final purchase-price allocation and goodwill assumptions.
- Developments in COVID-19-related customer spending and installations, as well as the cited litigation and cybersecurity, privacy, and supply risks.